Feb 23, 2017 at 17:54 | Source: Moneycontrol.com
Axis Direct recommended hold rating on Glaxosmithkline Consumer with a target price of Rs 5300 in its research report dated February 21, 2017.
Feb 20, 2017 at 13:25 | Source: Moneycontrol.com
Centrum is bearish on GlaxoSmithKline Pharma has recommended sell rating on the stock with a target price of Rs 1340 in its research report dated February 13, 2017.
Feb 20, 2017 at 08:26 | Source: CNBC-TV18
Idea Cellular | Axis Bank | Kotak Mahindra Bank | Hindustan Unilever | McNally Bharat | Havells | BPCL | GPT Infra | Mangalam Drugs and GSK Pharma are stocks, which are in the news today.
Feb 17, 2017 at 09:32 | Source: CNBC-TV18
Mahesh Nandurkar of CLSA expects FY18 Nifty earnings growth of 17 percent with small downside risk due to margin concern.
Feb 16, 2017 at 17:28 | Source: Moneycontrol.com
ICICI Direct is bullish on GSK Consumer has recommended buy rating on the stock with a target price of Rs 6102 in its research report dated February 14, 2017.
Feb 16, 2017 at 11:28 | Source: Moneycontrol.com
Edelweiss recommended hold rating on Glaxosmithkline with a target price of Rs 5773 in its research report dated February 13, 2017.
Feb 14, 2017 at 10:00 | Source: CNBC-TV18
CLSA has downgraded HPCL to sell from outperform, with increased target price at Rs 540 from Rs 480 and EPS for FY17 by 8 percent & by 1-2 percent for FY18-19. Core refining margin was disappointing for third straight quarter, the brokerage house says, adding it relaxed EV/EBITDA multiple to 7.5x from 7x earlier.
Feb 13, 2017 at 18:08 | Source: PTI
GlaxoSmithKline (GSK) ConsumerHealthcare Ltd today reported a 8.25 per cent decline in itsstandalone net profit at Rs 136.41 crore for the third quarterended on December 31, 2016, on the account of lower sales.
Feb 11, 2017 at 16:58 | Source: PTI
The company said mandatory price reductions experienced in the earlier quarters of the year had adversely impacted growth by 5 percent in the current quarter.
Feb 10, 2017 at 16:28 | Source: CNBC-TV18
Global drug major Novartis has invested, expanded its research & development (R&D) capabilities in India. The global leader in biosimilars through its subsidiary Sandoz is assessing Indian market dynamics to launch its portfolio.